Wells Fargo & Company Arcus Biosciences, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 18,614 shares of RCUS stock, worth $289,633. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,614

Previous 19,369 3.9%

Holding current value

$289,633

Previous $365,000 22.47%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$14.59 - $18.48 $11,015 - $13,952	-755 Reduced 3.9%	18,614 $283,000
Q1 2024 May 10, 2024	BUY	$14.83 - $20.18 $43,466 - $59,147	2,931 Added 17.83%	19,369 $365,000
Q4 2023 Feb 09, 2024	SELL	$13.43 - $19.63 $671,795 - $981,931	-50,022 Reduced 75.27%	16,438 $313,000
Q3 2023 Nov 13, 2023	SELL	$17.62 - $23.54 $163,636 - $218,615	-9,287 Reduced 12.26%	66,460 $1.19 Million
Q2 2023 Aug 15, 2023	SELL	$16.97 - $22.03 $96,253 - $124,954	-5,672 Reduced 6.97%	75,747 $1.54 Million
Q1 2023 May 12, 2023	BUY	$15.96 - $23.15 $1.25 Million - $1.81 Million	78,312 Added 2520.5%	81,419 $1.49 Million
Q4 2022 Feb 13, 2023	SELL	$19.7 - $35.71 $55,061 - $99,809	-2,795 Reduced 47.36%	3,107 $64,000
Q3 2022 Nov 14, 2022	BUY	$23.23 - $30.07 $3,577 - $4,630	154 Added 2.68%	5,902 $155,000
Q2 2022 Aug 12, 2022	SELL	$17.23 - $37.73 $409,074 - $895,785	-23,742 Reduced 80.51%	5,748 $145,000
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $395,828 - $572,527	-13,687 Reduced 31.7%	29,490 $930,000
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $164,086 - $253,449	5,229 Added 13.78%	43,177 $1.75 Million
Q3 2021 Nov 15, 2021	BUY	$26.93 - $37.68 $175,448 - $245,485	6,515 Added 20.73%	37,948 $1.32 Million
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $445,854 - $701,020	-19,598 Reduced 38.4%	31,433 $863,000
Q1 2021 May 13, 2021	SELL	$26.16 - $41.39 $1.5 Million - $2.37 Million	-57,254 Reduced 52.87%	51,031 $1.43 Million
Q4 2020 Feb 09, 2021	BUY	$17.0 - $32.36 $310,879 - $591,767	18,287 Added 20.32%	108,285 $2.81 Million
Q3 2020 Nov 05, 2020	BUY	$17.14 - $25.47 $31,589 - $46,941	1,843 Added 2.09%	89,998 $1.54 Million
Q2 2020 Aug 13, 2020	BUY	$13.97 - $36.56 $958,425 - $2.51 Million	68,606 Added 350.94%	88,155 $2.18 Million
Q1 2020 May 14, 2020	BUY	$8.78 - $19.28 $171,640 - $376,904	19,549 New	19,549 $271,000

Others Institutions Holding RCUS

# of Institutions

202

Shares Held

48.8M

Call Options Held

173K

Put Options Held

151K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.12B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Arcus Biosciences, Inc. Transaction History